Quantitatively-informed Socket Design Process

August 12, 2025 updated by: William Anderst, University of Pittsburgh

Improving Physical Function and Patient-reported Outcomes Through a Quantitatively-informed Socket Design Process

This study will investigate the effects of specific standardized modifications to trans-femoral prosthetic sockets in a randomized within-subject design. This is in preparation for a subsequently planned clinical trial to validate the findings by implementing them into a fitting method for individual sockets.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Background: Lower limb amputees experience chronic health challenges such as residual limb skin problems, low back pain, and osteoarthritis. These problems are exacerbated by high physical activity levels and by poor prosthetic socket fit. Prosthetists believe that limiting residual femur and skin motion will improve force coupling and thereby address these problems. However, there are no data demonstrating how changes in socket design affect residual femur and skin motion, and, by extension, lead to improved patient-reported outcomes.

Objective/Hypothesis: Goal of this research is to improve the current socket design optimization process that involves trial and error and relies heavily on the prosthetist's experience and intuition by using a quantitatively informed optimization process. The hypothesis is that modifiable in-socket mechanics, i.e. residual femur motion, skin strain, and pressure within the socket, are related to socket design and patient outcomes, and can be estimated using readily available clinical measurements.

Specific Aims: First aim is to identify the key characteristics of in-socket mechanics that are related to physical function and patient-reported comfort and function. The second aim is to identify readily available clinical measurements that are associated with the in-socket mechanical characteristics that are related to outcomes. The purpose of this aim is to correlate our laboratory findings from Aim 1 with more conventional modalities for clinical assessment.

Research Strategy: Preliminary data demonstrates the feasibility of the proposed research plan and will progress to a pilot clinical trial. The two aims will involve 30 transfemoral amputees. A highspeed biplane radiography system is used to image the residual limb while participants walk on a dual-belt instrumented treadmill both in their current socket and in sockets with purposely altered volume, brim height, cross-sectional geometry, and stiffness. Three-dimensional (3D) skin motion within the socket will be determined by tracking the motion of 40 to 50 small metal beads placed in a grid pattern on the skin of the residual limb before donning the socket. Residual femur motion within the socket will be determined with submillimeter accuracy using a validated tracking process that matches subject-specific bone models obtained from CT to the biplane radiographs. Discrete in-socket pressure will be recorded at four locations using pressure sensing pads. Readily available clinical measurements will be collected as well, including gait analysis, foot loading patterns, ground reaction forces, residual limb tissue stiffness, and hip range of motion hip strength. Each participant will complete clinical questionnaires to qualitatively evaluate comfort, fit, and overall satisfaction after wearing each socket. The different socket modifications are intended to affect the in-socket mechanics of the residual limb, physical function and patient-reported outcomes (Aim 1). These relationships will be assessed using a generalized linear model. Correlation between the research grade measurements and accessible clinical measures (Aim 2) will be evaluated using bivariate correlation analyses. The information gained in Aims 1 and 2 will be used to develop a quantitatively-informed socket optimization process, wherein the clinical measurements associated with in-socket mechanics will be used to inform socket design optimizations.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
8

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • United States
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15206
        • University of Pittsburgh
      • Pittsburgh, Pennsylvania, United States, 15328
        • Delatorre Orthotics & Prosthetics

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Transfemoral prosthesis user
  • 18-80 years of age
  • Body weight less than 125 kg
  • Able to walk unassisted on a treadmill

Exclusion Criteria:

  • Pregnant females
  • Clinically diagnosed osteoporosis
  • Previous high exposure to radiation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Unmodified Socket + 8 Socket Modifications in Random Order
The sequence of the 9 different interventions (original socket and 8 versions derived from it) is randomized for each participant. The number of participants is smaller than the number of possible permutations. Therefore the enacted ordering is randomly selected from the pool of possible orderings. Participants walk for less than 10 minutes with every socket type while data is being collected.
Device: Trans-femoral prosthetic socket

Unmodified) A custom-made check socket serving as the interface between residual limb and prosthesis

  1. Soft socket (Socket made from softer material than unmodified original)
  2. Stiff socket (Socket made from stiffer material than unmodified original)
  3. moderately lower brim height (Brim of the socket is lowered by 10% of socket length compared to unmodified original)
  4. slightly lower brim height (Brim of the socket is lowered by 5% of socket length compared to unmodified original)
  5. Oversized socket (The socket volume is 6% larger than the unmodified original)
  6. Undersized socket (The socket volume is 6% smaller than the unmodified original)
  7. CAT-CAM influenced geometry (The cross sectional geometry of the socket is modelled following the contoured adducted trochanteric-controlled alignment method (CAT-CAM))
  8. MAS influenced geometry (The cross sectional geometry of the socket is modelled following the Marlo Anatomic Socket (MAS) template)

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Residual Femur motion
Time Frame: 1 second
medial-lateral and superior-inferior translation of the distal femur relative to the socket from late swing through midstance
1 second
Skin strain
Time Frame: 1 second
average and peak skin strain within each of four regions, expressed as a percentage of the gait cycle
1 second
Socket pressure
Time Frame: 20 seconds
measure peak pressure and area under the pressure versus time curve, expressed as a percentage of the gait cycle
20 seconds

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Gait symmetry
Time Frame: 20 seconds
average of the peak trunk lean, and the average peak hip flexion and extension, measured by motion capture system
20 seconds
Plantar pressure
Time Frame: 20 seconds
peak plantar pressure from foot strike to midstance
20 seconds
Static displacement
Time Frame: 1 second
distance from the most distal point of the residual femur to the inside surface of the socket under weightbearing
1 second
Tissue Stiffness
Time Frame: 3 seconds
Average tissue stiffness for four regions of the residual limb
3 seconds
Trunk lean
Time Frame: 20 seconds
Body angles based on markers placed on the shoulders and spine
20 seconds
Hip flexion/extension
Time Frame: 20 seconds
Based on markers at greater trochanters, knee, ankle and foot.
20 seconds
Hip strength
Time Frame: 20 seconds
Manual muscle testing of hip flexors and extensors
20 seconds
Hip Range of Motion
Time Frame: 20 seconds
Manually measured using goniometer
20 seconds

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University of Pittsburgh

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
United States Department of Defense

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: William Anderst, PhD, University of Pittsburgh

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 1, 2021

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 1, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 12, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 3, 2021

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 3, 2021

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 13, 2021

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 14, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 12, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • STUDY20070123
  • W81XWH2010914 (Other Grant/Funding Number: US Dept of Defense)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified data may be shared with other researchers at Pitt in the future

IPD Sharing Time Frame

upon conclusion of the study (in 2025) with no expiration

IPD Sharing Access Criteria

commensurate with applicable restrictions posed by the study sponsor

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Artificial Limbs

Clinical Trials on Trans-femoral prosthetic socket

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings